Longitudinal Effect of Guselkumab on Biomarkers of Inflammation and Cardiovascular Risk in Bionaive Patients with Active Psoriatic Arthritis and High Systemic Inflammatory Burden: Post-hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-Controlled Study

被引：0
|
作者：
Kavanaugh, Arthur [1 ]
Soriano, Enrique [2 ,3 ]
Dutz, Jan [4 ]
Selmi, Carlo [5 ]
Rampakakis, Emmanouil [6 ]
Shiff, Natalie [7 ]
Nantel, Francois [8 ]
Lavie, Frederic [9 ]
Coates, Laura [10 ]
机构：
[1] Univ Calif San Diego, Div Rheumatol Allergy & Immunol, La Jolla, CA USA
[2] Hosp Italiano Buenos Aires, Internal Med Serv, Rheumatol Sect, Buenos Aires, DF, Argentina
[3] Univ Inst Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
[4] Vancouver Gen Hosp, Dept Dermatol & Skin Sci, Vancouver, BC, Canada
[5] Humanitas Univ, Humanitas Res Hosp Internal Med, Rheumatol & Clin Immunol, Rozzano, Italy
[6] McGill Univ, JSS Med Res, Sci Affairs, Dept Pediat, Montreal, PQ, Canada
[7] Univ Saskatchewan, Immunol, Janssen Sci Affairs LLC Adjunct, Horsham, PA USA
[8] Nantel Medsci Consult, Montreal, PQ, Canada
[9] Janssen Pharmaceut Companies Johnson & Johnson, Paris, France
[10] Univ Oxford, Oxford, England
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
BIOLOGIC-NAIVE;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2238
引用
收藏
页码：4421 / 4424
页数：4
相关论文
共 50 条
  • [31] Cardiovascular safety of vibegron, a new β3-adrenoceptor agonist, in older patients with overactive bladder: Post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study
    Yoshida, Masaki
    Takeda, Masayuki
    Gotoh, Momokazu
    Yokoyama, Osamu
    Kakizaki, Hidehiro
    Takahashi, Satoru
    Masumori, Naoya
    Nagai, Shinji
    Minemura, Kazuyoshi
    NEUROUROLOGY AND URODYNAMICS, 2021, 40 (06) : 1651 - 1660
  • [32] Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study
    Leng, Xiaomei
    Lin, Wei
    Liu, Shixue
    Kanik, Keith
    Wang, Cunshan
    Wan, Weiguo
    Jiang, Zhenyu
    Liu, Yi
    Liu, Shengyun
    Zhang, Zhuoli
    Zhang, Zhiyi
    Xu, Jian
    Tan, Wenfeng
    Hu, Jiankang
    Li, Jingyang
    Liu, Ju
    Gunay, Levent M.
    Dina, Oluwaseyi
    Kinch, Cassandra
    Zeng, Xiaofeng
    RMD OPEN, 2023, 9 (01):
  • [33] Ustekinumab in Patients with Active Psoriatic Arthritis: Results of the Phase 3, Multicenter, Double-Blind, Placebo-Controlled Psummit I Study
    Kavanaugh, Arthur
    McInnes, Iain B.
    Gottlieb, Alice B.
    Puig, Lluis
    Rahman, Proton
    Ritchlin, Christopher T.
    Li, Shu
    Wang, Yuhua
    Mendelsohn, Alan
    Doyle, Mittie K.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S1083 - S1084
  • [34] Ustekinumab in Patients with Active Psoriatic Arthritis: Results of the Phase 3, Multicenter, Double-blind, Placebo-Controlled PSUMMIT I Study
    Rahman, Proton
    Kavanaugh, Arthur
    Gottlieb, Alice
    Puig, Lluis
    Ritchlin, Christopher
    McInnes, Iain
    Li, Shu
    Wang, Yuhua
    Mendelsohn, Alan
    Doyle, Mittie
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (06) : 983 - 983
  • [35] USTEKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS OF THE PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PSUMMIT I STUDY
    McInnes, I. B.
    Kavanaugh, A.
    Gottlieb, A. B.
    Puig, L.
    Rahman, P.
    Ritchlin, C.
    Li, S.
    Wang, Y.
    Mendelsohn, A. M.
    Doyle, M. K.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 107 - 107
  • [36] Efficacy and safety of guselkumab, an anti-IL23 Monoclonal antibody, in patients with active psoriatic arthritis: A phase 2a, randomized, double-blind, placebo-controlled study
    Gottlieb, Alice
    Deodhar, Atul
    Boehncke, Wolf-Henning
    Dong, Bin
    Wang, Yuhua
    Barchuk, William
    Hsia, Elizabeth
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB111 - AB111
  • [37] EFFECT OF GUSELKUMAB ADMINISTERED EVERY 8 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS PERSISTS BETWEEN CONSECUTIVE DOSES AND IS DURABLE: POST HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY
    Mease, P. J.
    Baraliakos, X.
    Chandran, V.
    Soriano, E.
    Nash, P.
    Deodhar, A.
    Rampakakis, E.
    Shiff, N.
    Chakravarty, S. D.
    Shawi, M.
    Merola, J. F.
    Mcinnes, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1782 - 1783
  • [38] Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
    Kavanaugh, Arthur
    Lam, Gordon
    Tam, Lin-Shan
    Shiff, Natalie
    Lee, Youngja
    Perdomo, Ana-Maria Bravo
    Shawi, May
    Hsia, Elizabeth
    Rampakakis, Emmanouil
    Gutierrez, Carlos Enrique Toro
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4170 - 4172
  • [39] Longitudinal Evaluation of Neutrophil-to-Lymphocyte Ratio in Guselkumab-Treated Patients with Psoriatic Disease and Levels of Systemic Inflammation Associated with Elevated Cardiovascular Risk: Post-hoc Analysis of 4 Phase 3, Randomized, Controlled Studies
    Merola, Joseph
    Ogdie, Alexis
    Kavanaugh, Arthur
    Leibowitz, Evan
    Rampakakis, Emmanouil
    Funk, Ryan
    Nantel, Francois
    Lavie, Frederic
    Rowland, Katelyn
    Soriano, Enrique R.
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4760 - 4762
  • [40] Efficacy and safety of Guselkumab through 2 years: Results from a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis
    McInnes, I.
    Rahman, P.
    Gottlieb, A.
    Hsia, E.
    Kollmeier, A.
    Xu, X.
    Sheng, S.
    Jiang, Y.
    Shawi, M.
    Chakravarty, S.
    van der Heijde, D.
    Mease, P.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 38 - 38
12345